AGTC earnings

Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR, representing a premium of up to approximately 344% over AGTC's closing stock price on October 21, 2022 AGTC's Board has examined all alternative options for the future of AGTC and believes this transaction clearly delivers the best value for shareholders Given the state of equity and other funding markets, AGTC sees significant challenges in funding ongoing operations beyond 2022 Syncona and AGTC to host conference call on October 24, 2022 at 7:30 a.m. ET

– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited ret

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced financial results for the quarter ended December 31, 2021. "We enter 2022 with significant momentum from the recent buildout of our management team

AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patientsAt the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on improvements in visual sensitivity Totality of data from adult and pediatric patients indicate biologic activity and reaffirm previous positive safety findings in adultsCompany to host conference call to review data today at 8:00 a.m. ET GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commerci

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update. To acces

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022Initiating clinical safety evaluation of higher dosing for OTO-413 to support full dose-ranging Phase 2 efficacy trial expected to start by the end of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial r

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced financial results for the quarter ended September 30, 2021. "We have significant momentum toward achieving multiple clinical and regulatory milestones in the year ahead. We believe that the

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update. To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update. To access the call, dial (844) 646-2697 (US) or (918) 922-6902 (outside of the US). A live web

- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials - - Company on track to provide multiple data readouts for its XLRP and ACHM clinical programs in 2021 and 2022 - - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Company to host conference call and webcast today at 4:30 p.m. ET - GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conduct